Lilly’s Next Shot, Stacked on Zepbound, Took Off 23.3% of Body Weight
Patients with Type 2 diabetes usually lose less on GLP-1s. The combination study is trying to change that — and to do it with fewer side effects.
By Sean Anees Saifi · Capital Wealth · Published Thursday, October 1, 2026 · Source: The Wall Street Journal, Thursday, October 1, 2026 edition, whose market figures are the Wednesday, September 30 close
Key Points
A next-generation weight-loss drug from Eli Lilly (LLY), combined with Zepbound, helped people lose substantially more weight than Zepbound alone, Alex Janin reports, citing a new study.
The experimental injection, eloralintide, mimics amylin, a hormone that helps signal fullness after eating. It was studied with a Zepbound shot in patients with Type 2 diabetes.
Patients on the highest dose of the combination lost an average of 23.3% of body weight over roughly 11 months, versus 14.8% on Zepbound alone. The figure mixes patients who stayed in the trial and anticipated results for those who dropped out.
Dan Skovronsky, Lilly’s chief scientific officer, said the combination could be the most tolerable therapy the company has developed yet for the degree of weight loss expected. More drugmakers are testing amylin added to a GLP-1.
Patients with Type 2 diabetes historically lose less weight on GLP-1s than patients without diabetes. Lilly, which has the lead in the weight-loss-drug market, is also testing eloralintide as a stand-alone in separate late-stage studies.
23.3%
average weight loss on the highest-dose combination
14.8%
average loss on Zepbound alone in the same study
~11 mo.
study window for those figures
Amylin
the fullness hormone eloralintide is trying to mimic
23.3% versus 14.8% is a trial average, including people who quit. It is not a household dose.
In one line: Lilly’s amylin shot plus Zepbound beat Zepbound alone in a diabetes study. Pipeline is not a prescription, and 23.3% is not what a claim will pay.
Eli Lilly already leads the weight-loss-drug market. The next trick, the Journal reports, is stacking. Eloralintide, an experimental shot that mimics amylin — the hormone that says you’re full — was given with Zepbound to people with Type 2 diabetes. Highest dose of the combo: 23.3% average body-weight loss over about 11 months. Zepbound alone: 14.8%. Those averages blend patients who stayed and anticipated results for people who dropped out. Read that twice.
Diabetes patients historically lose less on GLP-1s than people without diabetes. That’s why a bigger number here would matter to the franchise. Other firms are running the same amylin-plus-GLP-1 idea, chasing more loss with fewer side effects. Lilly is also testing eloralintide by itself in late-stage studies. Dan Skovronsky, the company’s chief scientific officer, called the combination a turning point for the field and, in his view, potentially the most tolerable high-loss therapy they’ve built. That’s the inventor talking. The FDA hasn’t said it.
A trial average isn’t a prior authorization
This sits next to Tuesday’s Personal Journal piece on off-label microdoses for endometriosis pain. Different population, different vial, same household trap: treating a pipeline headline as if it were already in the pharmacy. Combination therapy, if it ever lands, will have a price, a prior auth, and a side-effect profile that didn’t appear in a paragraph about averages. Dropouts are in the 23.3%. So is the chance that your body isn’t the average.
Our read
Insurance (M11): don’t rearrange a 2027 medical budget around an experimental amylin shot. If someone in the house is already on Zepbound or Mounjaro, the useful sitting is the current prior auth, the copay, and the clinician of record — not a stacked trial. Pipeline news is for the statement of a stock you already own, not for a new household position. The house isn’t adding Lilly on a study.
If weight-loss drugs are a line in the cash-flow plan, keep paying for what is approved and covered. Put a date on the next specialist visit. Fifteen minutes with the explanation of benefits beats a 23.3% that includes the people who left.
What It Means For Your Portfolio
Hold — pipeline averages are not a prescription, and the house is not adding LLY
Zepbound plus an experimental amylin shot: 23.3% average loss versus 14.8% alone, in a diabetes study that counts dropouts as estimates.
General planning principles, not advice for anyone in particular. An 11-month trial average is not a household dose. If someone is already on a GLP-1, the work is the current prior authorization, the copay, and the clinician — not a stacked shot that is not approved. Do not spend a hoped-for 23.3%.
The house is not adding Eli Lilly on a study. If the stock is already in a book, that is a weight question, not a medical one. Keep medical cash on approved, covered care.
